- Home
- LSB vs LEXX Comparison
LSB vs LEXX Comparison
Compare LSB & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSB
- LEXX
- Stock Information
- Founded
- LSB 2002
- LEXX 2004
- Country
- LSB China
- LEXX Canada
- Employees
- LSB N/A
- LEXX N/A
- Industry
- LSB
- LEXX Biotechnology: Pharmaceutical Preparations
- Sector
- LSB
- LEXX Health Care
- Exchange
- LSB NYSE
- LEXX Nasdaq
- Market Cap
- LSB 22.3M
- LEXX 19.6M
- IPO Year
- LSB N/A
- LEXX N/A
- Fundamental
- Price
- LSB $0.95
- LEXX $0.86
- Analyst Decision
- LSB
- LEXX Strong Buy
- Analyst Count
- LSB 0
- LEXX 1
- Target Price
- LSB N/A
- LEXX $7.00
- AVG Volume (30 Days)
- LSB 19.7K
- LEXX 144.2K
- Earning Date
- LSB 07-07-2025
- LEXX 07-11-2025
- Dividend Yield
- LSB N/A
- LEXX N/A
- EPS Growth
- LSB N/A
- LEXX N/A
- EPS
- LSB N/A
- LEXX N/A
- Revenue
- LSB $79,415,311.00
- LEXX $525,923.00
- Revenue This Year
- LSB $39.33
- LEXX $0.62
- Revenue Next Year
- LSB $75.61
- LEXX $14.19
- P/E Ratio
- LSB N/A
- LEXX N/A
- Revenue Growth
- LSB N/A
- LEXX 29.95
- 52 Week Low
- LSB $0.36
- LEXX $0.82
- 52 Week High
- LSB $6.82
- LEXX $4.38
- Technical
- Relative Strength Index (RSI)
- LSB 37.75
- LEXX 31.77
- Support Level
- LSB $0.91
- LEXX $0.93
- Resistance Level
- LSB $1.03
- LEXX $1.05
- Average True Range (ATR)
- LSB 0.06
- LEXX 0.07
- MACD
- LSB 0.01
- LEXX -0.00
- Stochastic Oscillator
- LSB 46.88
- LEXX 14.14
About LSB LAKESHORE BIOPHARMA CO LTD
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.